WEBULL
WebtradeDownload

Learn Why The Bull Case For Siemens Healthineers Stock Could Change Following Liver Testing Partnership

Simply Wall St · 1d ago
  • Siemens Healthineers and Novo previously announced a collaboration to broaden non-invasive blood testing and awareness for MASLD and its progressive form MASH, aiming to reduce barriers to earlier disease assessment.
  • The tie-up directly targets growing demand for less invasive diagnostics in metabolic liver disease and reinforces Siemens Healthineers' focus on clinically integrated testing solutions that can strengthen its broader diagnostics portfolio.
  • We will now examine how this MASLD and MASH-focused collaboration might shape Siemens Healthineers' wider investment narrative around diagnostics and recurring revenues.

Compare Siemens Healthineers' diagnostics story with other potential compounders in healthcare by reviewing our curated list of 131 healthcare AI stocks.

Siemens Healthineers Investment Narrative Recap

To own Siemens Healthineers, you need to be comfortable with a story built around steady adoption of imaging, diagnostics and therapy systems, supported by recurring service and software income. The Siemens Healthineers and Novo MASLD collaboration fits that script, but the incremental revenue impact looks limited near term. The more immediate swing factor still sits in execution on Diagnostics restructuring and margin repair.

The biggest operational risk remains pressure from tariffs, China pricing reforms and foreign exchange, which can all squeeze profitability while mitigation plans take time. This new MASLD blood testing push does not change those external headwinds. It mainly reinforces the existing diagnostics focus, rather than shifting the near term risk reward balance.

With no other recent company announcements flagged around diagnostics, the MASLD and MASH collaboration itself becomes the key reference point. It aligns with Siemens Healthineers' effort to move laboratories toward integrated, higher value testing and informatics, which can deepen relationships with hospitals and support more predictable service and consumables demand.

For you as an investor, the operational question is whether this type of partnership can scale into recurring test volumes without adding too much complexity or cost. Execution in markets such as China, where diagnostics pricing faces structural pressure, will matter. If uptake of less invasive liver tests is slow or reimbursement is tight, the catalyst from this announcement could remain modest.

Siemens Healthineers' analyst narrative points to revenues of €27.5b and earnings of €3.0b by 2029, based on 6.1% yearly revenue growth and an earnings increase of about €0.9b from €2.1b today.

Uncover why Siemens Healthineers' fair value indicates a 20% potential upside to its current price that could narrow quickly.

XTRA:SHL 1-Year Stock Price Chart
XTRA:SHL 1-Year Stock Price Chart

Exploring Other Perspectives

Some analysts look at Siemens Healthineers and focus less on upside from MASLD blood testing and more on how heavy R&D and big equipment projects could cap profitability. The most cautious group was pencilling in €27.5b of revenue and only €2.7b of earnings by 2029. That is quite different from consensus, and both views were formed before this collaboration, so forecasts may shift as investors reassess the diagnostics story.

Explore 2 other Siemens Healthineers fair value estimates, including one that suggests it could be worth just €45.52.

Decide For Yourself

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Siemens Healthineers?

If you want to pressure test your view on Siemens Healthineers against other opportunities, it can help to scan a wider set of companies with different risk and income profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.